Italy's DiaSorin ex-Covid revenue in line with guidance

Health

Italy’s DiaSorin ex-Covid revenue in line with guidance

Fri, Mar 14, 2025 0 Comments

Audio By Carbonatix

(Reuters) -Italian medical diagnostics group DiaSorin on Friday reported a 3% rise in 2024 revenue, citing dampened demand for its products with a milder Flu season compared to the previous year.

The group’s 2024 revenue increased 3% year-on-year at constant exchange rates to 1.18 billion euros ($1.28 billion), while revenue was up 7% when excluding its COVID-related business, in line with guidance.

The group proposed a dividend of 1.20 euro per share.

Shares were 2.6% lower after the results.

(Reporting by Michela Stasio; Editing by Kirsten Donovan)

Previous NFL transactions roundup: Lions, WR Tim Patrick stick together

Next US IRS pauses modernization investments to evaluate AI technology

Salem News Channel | Today

More Health Headlines

Other News to Consider

Follow SRNNews.com

on Facebook

@SRNNews

Subscribe to our Newsletters RSS Feeds

Editorial Cartoons

Salem Media, our partners, and affiliates use cookies and similar technologies to enhance your browsing experience, analyze site traffic, personalize site content, and deliver relevant video recommendations. By using this website and continuing to navigate, you consent to our use of such technologies and the sharing of video viewing activity with third-party partners in accordance with the Video Privacy Protection Act and other privacy laws. Privacy Policy

X CLOSE

Email to a Friend

Italy’s DiaSorin ex-Covid revenue in line with guidance

(Reuters) -Italian medical diagnostics group DiaSorin on Friday reported a 3% rise in 2024 revenue, citing dampened demand for its products with a milder Flu season compared to the previous year. The group’s 2024 revenue increased 3% year-on-year at constant exchange rates to 1.18 billion euros ($1.28 billion), while revenue was up 7% when excluding […]

X close